Chibby, a novel antagonist of the Wnt pathway, is not involved in Wilms tumor development.

Abstract excerpt

Deregulation of the Wnt signalling pathway is a key event in the development of a broad spectrum of human malignancies and mutations in beta-catenin (CTNNB1), a central component of the Wnt pathway, have been detected in 10-15% of Wilms tumors (nephroblastoma). Furthermore, nuclear immunoreactivity for beta-catenin has been described even in the absence of detectable beta-catenin mutations. This suggests that...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carrier Proteins
• Share to Intercellular Signaling Peptides and Proteins